Indian pharmaceutical equities faced renewed selling pressure on Friday, July 24, as markets digested the implications of US President Donald Trump’s phased tariff plan for imported generic medicines.
The policy, which threatens to escalate duties from zero to 200 percent by 2028, has cast a shadow over the outlook for Indian exporters heavily reliant on the US market.
Abbott India led the losses, with shares falling 3.69 percent.
Alembic Pharma and Ajanta Pharma also saw significant declines, with some pharma stocks dropping up to 4 percent in the session.
The broad-based selloff reflects growing investor anxiety over the potential erosion of margins and market share for Indian manufacturers if the tariffs are fully implemented.
The market reaction follows a sharp sell-off on Wednesday, when the Nifty Pharma index dropped nearly 2 percent after the initial announcement of the tariff regime.